The endocannabinoid system (ECS) is a widespread biological signaling network that exists in every human body, regardless of whether a person has ever used cannabis. It consists of three core parts: cannabinoid receptors embedded in cell membranes throughout the body, naturally produced molecules called endocannabinoids that activate those receptors, and enzymes that build and break down those molecules. The system was only identified in the 1990s, but it turns out to be one of the body’s most important tools for maintaining internal balance, influencing everything from pain perception and stress responses to appetite and memory.
How Scientists Stumbled Onto It
The endocannabinoid system was discovered backward, starting with the plant rather than the body. In 1964, researchers in Israel isolated THC, the main psychoactive compound in cannabis, and determined its chemical structure. That breakthrough set off a decades-long hunt for why the human brain responds to a plant compound at all. The answer came when scientists found that human cells carry specific receptors that THC binds to, and then discovered that the body produces its own molecules designed to activate those same receptors. The term “endocannabinoid” was coined in the mid-1990s to describe this entire signaling apparatus: the receptors, the body’s own cannabis-like molecules, and the enzymes that manage them.1Nature Reviews Drug Discovery. The endocannabinoid system and its therapeutic exploitation The naming is a bit unfortunate because it makes it sound like the system exists for cannabis, when in reality cannabis hijacks a system that evolved for entirely different purposes.
Where the Receptors Are
The two main cannabinoid receptors, CB1 and CB2, sit on cell surfaces throughout the body, but they concentrate in very different places and serve different roles.
CB1 receptors are the most abundant type and are densely packed in the brain. Detailed mapping of the human brain shows they are not evenly spread: the hippocampus (involved in memory), the amygdala (involved in emotional processing), and the associational cortex regions of the frontal and temporal lobes all carry high concentrations of CB1 receptors. Primary sensory and motor areas have lower densities.2Neuroscience. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain This distribution explains a lot about what cannabis does to people: the high receptor density in memory regions is why THC impairs short-term memory, while the relatively low density in brainstem areas controlling breathing is why cannabis overdoses are rarely lethal. Within the brain’s circuits, CB1 receptors appear on both inhibitory and excitatory nerve terminals, though the signal is stronger on inhibitory ones.3Scientific Reports. Cell type specific cannabinoid CB1 receptor distribution across the human and non-human primate cortex
CB2 receptors tell a different story. They are found mainly on immune cells: B cells, natural killer cells, macrophages, and T cells, as well as in immune-related tissues like the tonsils and thymus. Under normal conditions, CB2 receptors are barely detectable in the brain. But when the brain becomes inflamed, microglia (the brain’s resident immune cells) ramp up CB2 expression, and immune cells from the rest of the body that cross into the brain during inflammation add more.4Expert Reviews in Molecular Medicine. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation This pattern suggests that CB2 is less about day-to-day brain function and more about damage control when something goes wrong.
The Body’s Own Cannabinoids
Your body makes at least two well-studied endocannabinoids: anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Both are built from fat-based precursors already sitting in cell membranes, and they are produced on demand rather than stored in advance.5Nature Reviews Neuroscience. The molecular logic of endocannabinoid signalling When a neuron needs to send a cannabinoid signal, it cleaves these molecules from the membrane, they do their work, and they are quickly broken down.
Anandamide (named after the Sanskrit word for bliss) is synthesized through a multi-step process involving membrane phospholipids, and it is broken down primarily by an enzyme called FAAH, which splits it into arachidonic acid and ethanolamine.6Frontiers in Molecular Neuroscience. Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years The fact that FAAH sits on the cell’s internal membranes means anandamide gets pulled inside the cell by the concentration gradient created as FAAH chews it up.7PubMed Central. A Personal Retrospective: Elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs)
2-AG is present in the brain at much higher levels than anandamide and is broken down by a different enzyme, MAGL, which accounts for roughly 85% of 2-AG breakdown in mouse brain tissue. The remaining activity comes from a few less-studied enzymes.8Cell Chemical Biology. A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol This quick production-and-destruction cycle is central to how the system works: endocannabinoids act locally, briefly, and then vanish. They are not like hormones that circulate through the bloodstream for hours.
Backward Signaling at Synapses
The most distinctive thing the endocannabinoid system does in the brain is run communication backward. Most neurotransmitters travel from a sending neuron to a receiving one. Endocannabinoids do the opposite: the receiving neuron releases them, and they travel backward to the sending neuron, where they bind to CB1 receptors on the presynaptic terminal. This retrograde signaling is the main way endocannabinoids shape brain activity.9PubMed Central. Endocannabinoid signaling and synaptic function
An early demonstration of this came from work on the hippocampus showing that when pyramidal neurons depolarize, they release endocannabinoids that temporarily suppress incoming inhibitory signals from neighboring neurons.10Nature. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses Think of it as a volume knob: when a receiving neuron is getting too much input, it sends endocannabinoids backward to tell the sending neuron to quiet down. This happens at both excitatory and inhibitory connections, and it can produce short-lived effects lasting seconds or longer-lasting changes in how strongly two neurons are connected.11PubMed. Endocannabinoid-mediated synaptic plasticity in the CNS
A 2024 study confirmed this process works during actual behavior, not just in brain slices on a lab bench. In mice running along a track, researchers observed endocannabinoid signaling at specific locations tied to hippocampal place cells, the neurons that map where an animal is in space. The signaling suppressed inhibitory inputs on a timescale of seconds, and when CB1 receptors were deleted from inhibitory interneurons specifically, place cell activity changed.12PubMed Central. Retrograde endocannabinoid signaling at inhibitory synapses in vivo So the endocannabinoid system is not just capable of fine-tuning neural circuits in theory; it is doing so in real time as animals navigate their environment.
What the System Regulates
Because CB1 and CB2 receptors are spread across so many tissues, the endocannabinoid system touches a remarkably wide range of body functions. The common thread is homeostasis: the system tends to act as a buffer, nudging things back toward a set point rather than pushing them in one direction.
Pain is one of the best-studied areas. Endocannabinoids influence pain processing both in the brain and in peripheral tissues, acting through CB1 receptors in the central nervous system and CB2 receptors in immune cells at sites of injury or inflammation.13PubMed Central. The endocannabinoid system, cannabinoids, and pain This dual action helps explain why cannabis has been used for pain relief across many cultures, and why researchers are interested in developing drugs that boost endocannabinoid levels rather than introducing external cannabinoids.
Stress responses are another key domain. The endocannabinoid system plays a direct role in regulating the hypothalamic-pituitary-adrenal (HPA) axis, the body’s primary stress-hormone cascade. Research indicates that endocannabinoid signaling both activates and helps terminate stress-hormone release, acting in the prefrontal cortex, amygdala, and hypothalamus to suppress HPA axis activity overall.14Neuroscience. Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis In plainer terms, endocannabinoids help the body shift from “threat detected” back to calm. This is consistent with the well-known anxiolytic (anxiety-reducing) effects of cannabis at low doses, and the paradoxical anxiety or paranoia that can occur at high doses when the system gets overwhelmed.
Appetite and energy balance round out the picture. Endocannabinoids acting through CB1 receptors in the hypothalamus and limbic forebrain contribute to hunger-driven eating. Studies in rodents found that this signaling is negatively regulated by leptin, a hormone that signals satiety.15PubMed. The role of the endocannabinoid system in the control of energy homeostasis When leptin levels are low (as in starvation), endocannabinoid tone rises, driving appetite. When leptin levels are high, endocannabinoid activity falls. This interplay between hunger hormones and the ECS is a key reason why cannabis famously causes the munchies.
Receptors Beyond CB1 and CB2
The classical picture of CB1 and CB2 as the only endocannabinoid receptors has expanded considerably. Anandamide in particular turns out to be quite promiscuous, interacting with several other receptor types. These include certain transient receptor potential (TRP) channels, especially TRPV1 (sometimes called the capsaicin receptor, since it is also what makes chili peppers feel hot), and orphan receptors like GPR55.16PubMed. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels
TRPV1 is particularly interesting because it sits on sensory nerve fibers throughout the body, including in arthritic joint tissue, where endocannabinoids can modulate pain signaling through it.17PubMed Central. Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis TRPV1 also shows up in epilepsy research: in patients with temporal lobe epilepsy, TRPV1 expression is significantly reduced in the neocortex, suggesting the receptor plays a meaningful role in seizure-related brain circuits.18PubMed Central. In silico analyses of the involvement of GPR55, CB1R and TRPV1: response to THC, contribution to temporal lobe epilepsy, structural modeling and updated evolution The expanding receptor landscape means the endocannabinoid system is more like a web of overlapping signaling pathways than a single on-off switch.
How Cannabis Compounds Interact with the System
THC, CBD, and other plant cannabinoids each interact with the endocannabinoid system in distinct ways, and the details matter because they explain why these compounds produce such different effects.
THC is a partial agonist at both CB1 and CB2 receptors, meaning it activates them but not as fully as the body’s own endocannabinoids can under maximal conditions. The responses THC produces depend heavily on how many receptors a given tissue has and how efficiently those receptors signal. In tissues with high receptor density, THC can produce strong effects; in tissues with fewer receptors, the same dose may do very little.19PubMed Central. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin
CBD is more surprising. Rather than activating CB1 or CB2 receptors, it acts as an antagonist with unexpectedly high potency, blocking other compounds from activating them. Its interactions with CB2 receptors may help explain its reported effects on immune cell movement and inflammation. Another plant cannabinoid, THCV (delta-9-tetrahydrocannabivarin), adds another wrinkle: it behaves as a partial agonist at CB2 but antagonizes CB1 in brain tissue.19PubMed Central. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin This is why describing cannabis effects as simply “activating the endocannabinoid system” is misleading. Different compounds in the same plant push and pull the system in opposite directions at different receptor types.
Exercise and the Runner’s High
For years the runner’s high was attributed to endorphins, but endocannabinoids are now a leading contender. A review of the available studies found that 14 out of 17 studies detected an increase in circulating endocannabinoids after a single bout of exercise.20PubMed Central. Do Endocannabinoids Cause the Runner’s High? Evidence and Open Questions Endocannabinoids are small, fat-soluble molecules that can cross the blood-brain barrier, unlike endorphins, which cannot easily get from the bloodstream into the brain. That makes endocannabinoids a more plausible explanation for the mood boost, reduced anxiety, and mild euphoria that follow vigorous exercise.
The picture changes with long-term training, however. Among studies examining chronic endurance exercise over weeks or months, four described a decrease in baseline endocannabinoid levels.20PubMed Central. Do Endocannabinoids Cause the Runner’s High? Evidence and Open Questions Endocannabinoids generated during high-intensity activity seem to function as short-term circuit breakers, producing brief pain-dampening effects.21PubMed Central. The Endocannabinoid System and Physical Exercise So a single hard workout reliably spikes endocannabinoid levels, but becoming a trained endurance athlete may shift baseline tone in a different direction. The field is still sorting out what that means for long-term mood and pain regulation in athletes.
Clinical Endocannabinoid Deficiency
One of the more provocative ideas to come out of ECS research is the clinical endocannabinoid deficiency (CED) hypothesis. The basic claim is that some people, whether from genetics or life circumstances, have chronically low endocannabinoid tone, meaning their baseline levels of anandamide and 2-AG, the density of their receptors, or the efficiency of the system’s enzymes are below what is needed for normal function. The hypothesis originally proposed that this deficiency underlies conditions like migraine, fibromyalgia, and irritable bowel syndrome, all of which share features of heightened pain sensitivity and central sensitization.22PubMed Central. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes
Research on fibromyalgia specifically has examined whether patients show measurable ECS dysregulation, including altered endocannabinoid levels and receptor activity, though the evidence remains preliminary.23PubMed Central. Role of the Endocannabinoid System in Fibromyalgia The CED hypothesis is attractive because it would explain why some patients respond to cannabinoid-based treatments when other drugs fail, but it remains a framework rather than a proven diagnosis. No standard clinical test for endocannabinoid tone exists yet, and the conditions associated with CED are defined by their symptoms rather than a known biomarker.
Drug Development Beyond Cannabis
Rather than flooding the system with THC, one strategy pharmaceutical researchers are pursuing is to slow down the enzymes that break down endocannabinoids, letting the body’s own molecules stick around longer. Blocking FAAH raises anandamide levels; blocking MAGL raises 2-AG levels. Both approaches can amplify endocannabinoid signaling indirectly, potentially producing therapeutic effects without the psychoactive side effects that come from directly activating CB1 receptors with THC.24PubMed. Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors
The appeal of this approach is that it works with the body’s existing signaling rather than overriding it. Endocannabinoids are produced on demand at specific locations, so raising their levels by slowing their breakdown should amplify the signal only where and when the body is already producing it. This is fundamentally different from taking THC, which activates CB1 receptors everywhere in the brain simultaneously. Early research suggests that FAAH and MAGL inhibitors may help restore normal endocannabinoid tone in conditions where it has become disrupted, including certain substance use disorders.25Neurotherapeutics. FAAH and MAGL inhibition: Evolving approaches to treating substance use disorders Drug development in this space has had setbacks, though. A 2016 clinical trial of a FAAH inhibitor in France led to one participant’s death and several hospitalizations, an event later attributed to the drug hitting targets well beyond FAAH. The episode underscored how little margin for error exists when manipulating a system this deeply embedded in brain function.
The ECS Across the Lifespan
The endocannabinoid system is not something that turns on at adulthood and stays static. It is present from the earliest stages of embryonic development, where it helps guide the formation of the nervous system. During fetal life, endocannabinoids and CB1 receptors regulate neural progenitor differentiation, helping determine which stem cells become neurons, and they guide axonal migration, the process by which developing nerve fibers find their targets.26PubMed. The endocannabinoid system during development: emphasis on perinatal events and delayed effects The system has been detected from the earliest embryonic stages and continues to play roles throughout prenatal and postnatal development.27PubMed Central. Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration This is part of why cannabis use during pregnancy raises concerns: introducing THC when the fetal brain is using endocannabinoid signaling to wire itself could potentially disrupt normal developmental processes.
At the other end of the lifespan, endocannabinoid levels shift with age. A study comparing younger, midlife, and older adults found that older adults had lower baseline levels of anandamide and other related fatty acid molecules compared to younger adults, even after adjusting for body weight and other lifestyle factors.28PubMed Central. Age differences in endocannabinoid tone are ameliorated after recent cannabis use Age-related changes in the endocannabinoid system have also been explored in the context of neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s, though findings in Alzheimer’s specifically have been mixed and inconsistent across human studies.29PubMed. Endocannabinoid system alterations in Alzheimer’s disease: A systematic review of human studies The aging brain undergoes gradual changes in ECS components, which may contribute to some degree of normal age-related cognitive decline independent of any neurodegenerative disorder.30Integrative Neurology. The Endocannabinoid System in the Aging Brain and Neurodegenerative Diseases
An Ancient Biological System
The endocannabinoid system did not appear recently in evolutionary terms, but its components did not all appear at the same time. The enzymes that build and break down endocannabinoid molecules are found throughout the animal kingdom, suggesting they are very old. The endocannabinoid molecules themselves appear to have evolved independently multiple times in different lineages. CB1 and CB2 receptors, however, seem to be unique to chordates (the group that includes all vertebrates plus a few relatives like sea squirts). In the sea squirt Ciona intestinalis, a CB1/CB2-type receptor is already localized to axons, hinting that regulating nerve signaling was the system’s original job.31PubMed Central. The evolution and comparative neurobiology of endocannabinoid signalling
The fruit fly Drosophila and the roundworm C. elegans, two of the most studied invertebrates, do not have CB1-type receptors in their genomes, which suggests that these receptors either evolved after the split between the vertebrate lineage and the insect/worm lineage, or were lost in those groups.32PubMed Central. The neurobiology and evolution of cannabinoid signalling A broader chemotaxonomic analysis puts the origin of CB receptors somewhere before the split between organisms like Hydra and more complex bilateral animals, with a secondary loss in insects and nematodes.33Brain Research Reviews. Phylogenomic and chemotaxonomic analysis of the endocannabinoid system What emerged from that analysis is a layered timeline: endocannabinoid ligands came first, the receptors came later, and the cleanup enzyme FAAH appears to be the newest piece, evolving only after the emergence of vertebrates. The system we carry today is the product of hundreds of millions of years of tinkering, which is one reason it is so deeply woven into so many different body functions.